Recombinant PfEMP1 peptide inhibits and reverses cytoadherence of clinical Plasmodium falciparum isolates in vivo.

The parasite ligand Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) and host endothelial receptors represent potential targets for antiadhesive therapy for cytoadherence. In the present study, the major host receptor CD36 was targeted in vitro and in vivo with a recombinant peptide, PpMC-179, corresponding to the minimal CD36-binding domain from the cysteine-rich interdomain region 1 (CIDR1) within the MCvar1 PfEMP1. The in vitro inhibitory effect of PpMC-179 on human dermal microvascular endothelial cells (HDMECs) expressing multiple relevant adhesion molecules was investigated using a parallel-plate flow chamber. Pretreatment of endothelial monolayers with PpMC-179 (2 microM) inhibited the adhesion of infected erythrocytes (IRBCs) from all clinical isolates tested by 84.4% on resting and 62.8% on tumor necrosis factor alpha (TNF-alpha)-stimulated monolayers. Adhesion to stimulated cells was further inhibited (90.4%) when PpMC-179 was administered with an inhibitory anti-intercellular adhesion molecule 1 (ICAM-1) monoclonal antibody 84H10 (5 microg/mL). To determine the in vivo effectiveness of PpMC-179, we used a human/severe combined immunodeficiency (SCID) mouse chimeric model that allowed direct visualization of cytoadherence on intact human microvasculature. In unstimulated skin grafts, PpMC-179 inhibited adhesion by 86.3% and by 84.6% in TNF-alpha-stimulated skin grafts. More importantly, PpMC-179 administration resulted in the detachment of already adherent IRBCs by 80.7% and 83.3% on resting and stimulated skin grafts, respectively. The antiadhesive effect of PpMC-179 was rapid and sustained in vivo for at least 30 minutes. Our data indicate that targeting cytoadhesion in vivo is feasible and may offer a rapid antimalarial therapy.

[1]  S. Satpathy,et al.  Severe falciparum malaria , 2004, Indian journal of pediatrics.

[2]  D. Blazes,et al.  Exchange transfusion as an adjunct therapy in severe Plasmodium falciparum malaria: a meta-analysis. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  B. Gamain,et al.  Immunization of Aotus monkeys with a functional domain of the Plasmodium falciparum variant antigen induces protection against a lethal parasite line , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[4]  B. Gamain,et al.  Decoding the language of var genes and Plasmodium falciparum sequestration. , 2001, Trends in parasitology.

[5]  B. Gamain,et al.  Modifications in the CD36 binding domain of the Plasmodium falciparum variant antigen are responsible for the inability of chondroitin sulfate A adherent parasites to bind CD36. , 2001, Blood.

[6]  B. Gamain,et al.  The surface variant antigens of Plasmodium falciparum contain cross-reactive epitopes , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[7]  A. Beaudet,et al.  Severe inflammatory defect and reduced viability in CD18 and E-selectin double-mutant mice. , 2000, The Journal of clinical investigation.

[8]  P. Kubes,et al.  Visualization of Plasmodium falciparum–Endothelium Interactions in Human Microvasculature , 2000, The Journal of experimental medicine.

[9]  N. Day,et al.  The prognostic and pathophysiologic role of pro- and antiinflammatory cytokines in severe malaria. , 1999, The Journal of infectious diseases.

[10]  L. Miller,et al.  CD36 peptides that block cytoadherence define the CD36 binding region for Plasmodium falciparum-infected erythrocytes. , 1999, Blood.

[11]  S. Krudsood,et al.  Polyclonal anti-tumor necrosis factor-alpha Fab used as an ancillary treatment for severe malaria. , 1999, The American journal of tropical medicine and hygiene.

[12]  R. Coppel,et al.  A recombinant peptide based on Pf EMP‐1 blocks and reverses adhesion of malaria‐infected red blood cells to CD36 under flow , 1998, Molecular microbiology.

[13]  A. Scherf,et al.  Antigenic variation in malaria: in situ switching, relaxed and mutually exclusive transcription of var genes during intra‐erythrocytic development in Plasmodium falciparum , 1998, The EMBO journal.

[14]  P. Kubes,et al.  Characterization of Plasmodium falciparum-infected erythrocyte and P-selectin interaction under flow conditions. , 1998, Blood.

[15]  W. Wernsdorfer,et al.  Pentoxifylline as an ancillary treatment for severe falciparum malaria in Thailand. , 1998, The American journal of tropical medicine and hygiene.

[16]  C. Newbold,et al.  Intercellular adhesion molecule-1 and CD36 synergize to mediate adherence of Plasmodium falciparum-infected erythrocytes to cultured human microvascular endothelial cells. , 1997, The Journal of clinical investigation.

[17]  H. Singh,et al.  Identification of a region of PfEMP1 that mediates adherence of Plasmodium falciparum infected erythrocytes to CD36: conserved function with variant sequence. , 1997, Blood.

[18]  J. Gysin,et al.  Chondroitin-4-Sulfate Impairs In Vitro and In Vivo Cytoadherence of Plasmodium falciparum Infected Erythrocytes , 1997, Molecular medicine.

[19]  P. Kubes,et al.  Promiscuity of clinical Plasmodium falciparum isolates for multiple adhesion molecules under flow conditions. , 1997, Journal of immunology.

[20]  D. Kwiatkowski,et al.  The effect of a monoclonal antibody to tumor necrosis factor on survival from childhood cerebral malaria. , 1996, The Journal of infectious diseases.

[21]  N. White,et al.  Receptor specificity of clinical Plasmodium falciparum isolates: nonadherence to cell-bound E-selectin and vascular cell adhesion molecule-1. , 1996, Blood.

[22]  L. Daviet,et al.  Identification of a Domain (155–183) on CD36 Implicated in the Phagocytosis of Apoptotic Neutrophils* , 1996, The Journal of Biological Chemistry.

[23]  D. Baruch,et al.  Plasmodium falciparum erythrocyte membrane protein 1 is a parasitized erythrocyte receptor for adherence to CD36, thrombospondin, and intercellular adhesion molecule 1. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Theodore F. Taraschi,et al.  Cloning the P. falciparum gene encoding PfEMP1, a malarial variant antigen and adherence receptor on the surface of parasitized human erythrocytes , 1995, Cell.

[25]  X. Su,et al.  The large diverse gene family var encodes proteins involved in cytoadherence and antigenic variation of plasmodium falciparum-infected erythrocytes , 1995, Cell.

[26]  C. Diggs,et al.  Plasmodium falciparum: passive immunization of Aotus lemurinus griseimembra with immune serum. , 1995, Experimental parasitology.

[27]  Davis,et al.  An immunohistochemical study of the pathology of fatal malaria. Evidence for widespread endothelial activation and a potential role for intercellular adhesion molecule-1 in cerebral sequestration. , 1994, The American journal of pathology.

[28]  J. Pober,et al.  Human T-cell-mediated destruction of allogeneic dermal microvessels in a severe combined immunodeficient mouse. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[29]  T. Springer,et al.  Pathway of rhinovirus disruption by soluble intercellular adhesion molecule 1 (ICAM-1): an intermediate in which ICAM-1 is bound and RNA is released , 1994, Journal of virology.

[30]  J. Pober,et al.  Heterogeneity of dermal microvascular endothelial cell antigen expression and cytokine responsiveness in situ and in cell culture. , 1993, Journal of immunology.

[31]  L. Anderson,et al.  Cytoadherence by Plasmodium falciparum-infected erythrocytes is correlated with the expression of a family of variable proteins on infected erythrocytes , 1988, The Journal of experimental medicine.

[32]  M. Aikawa.  Human cerebral malaria. , 1988, The American journal of tropical medicine and hygiene.

[33]  N. White,et al.  Human cerebral malaria. A quantitative ultrastructural analysis of parasitized erythrocyte sequestration. , 1985, The American journal of pathology.

[34]  L. Miller,et al.  Parasite sequestration in Plasmodium falciparum malaria: spleen and antibody modulation of cytoadherence of infected erythrocytes. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[35]  B. Gamain,et al.  Modifications in the CD 36 binding domain of the Plasmodium falciparum variant antigen are responsible for the inability of chondroitin sulfate A adherent parasites to bind CD 36 , 2001 .

[36]  M. Ho,et al.  Synergism of multiple adhesion molecules in mediating cytoadherence of Plasmodium falciparum-infected erythrocytes to microvascular endothelial cells under flow. , 2000, Blood.

[37]  F. Canovas,et al.  In vivo migration of tonsil lymphocytes in rheumatoid synovial tissue engrafted in SCID mice: involvement of LFA-1. , 1996, Autoimmunity.

[38]  N. White,et al.  The pathophysiology of malaria. , 1992, Advances in parasitology.

[39]  R. D. Isaacs,et al.  Severe falciparum malaria. , 1986, The New Zealand medical journal.